PPOH
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: 9 μM for the formation of arachidonate 11,12 epoxides by CYP4A2 and CYP4A3 enzymes, respectively
PPOH is an inhibitor of CYP epoxidase activity on arachadonic acid.
Arachidonic acid can be converted by microsomal CYP450 enzymes to a variety of epoxides, ω-1 and ω-hydroxylated compounds through what is reported as the epoxidase pathway.
In vitro: A previous study found that the inhibition of the epoxygenase pathway with PPOH was able to enhance the microvascular response to increasing renal perfusion pressure. In the presence of 50 mM PPOH, afferent arteriolar diameter decreased by 29% when pressure was increased from 80-160 mmHg. In contrast, the selective CYT-P450 hydroxylase inhibitor, N-methylsulphonyl-12,12-dibromododec-11-enamide could attenuate the vascular response to increasing renal perfusion pressure [1]. In another study, it was shown that among the acetylenic compounds, both PPOH and N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide were potent and selective inhibitors of microsomal epoxidation with IC50 values of 9 and 13 microM, respectively. Inhibition of microsomal activity by PPOH, but not DDMS, was time- and NADPH-dependent, which was a characteristic of a mechanism-based irreversible inhibitor [2].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Imig, J. D.,Falck, J.R., and Inscho, E.W. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. British Journal of Pharmacology 127, 1399-1405 (1999).
[2] Wang, M. H.,Brand-Schieber, E.,Zand, B.A., et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: Characterization of selective inhibitors. Journal of Pharmacology and Experimental Therapeutics 284(3), 966-973 (1998).
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 246.3 |
Cas No. | 206052-01-9 |
Formula | C15H18O3 |
Solubility | ≤100mg/ml in ethanol;50mg/ml in DMSO;100mg/ml in dimethyl formamide |
Chemical Name | 2-(2-propynyloxy)-benzenehexanoic acid |
SDF | Download SDF |
Canonical SMILES | C#CCOC1=CC=CC=C1CCCCCC(O)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |